Csenge Advisory Group’s GSK GSK Stock Holding History

Csenge Advisory Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.18M	Buy	41,506 +5,720	+16%	+$303K	0.09%	196
2026 Q1	$1.98M	Sell	35,786 -9,604	-21%	-$520K	0.09%	181
2025 Q4	$2.23M	Buy	45,390 +4,557	+11%	+$213K	0.1%	176
2025 Q3	$1.76M	Buy	40,833 +13,684	+50%	+$535K	0.08%	189
2025 Q2	$1.11M	Buy	27,149 +2,402	+10%	+$91.8K	0.06%	248
2025 Q1	$889K	Buy	24,747 +4,606	+23%	+$169K	0.05%	274
2024 Q4	$681K	Buy	20,141 +2,423	+14%	+$87.2K	0.04%	355
2024 Q3	$688K	Sell	17,718 -2,645	-13%	-$108K	0.04%	357
2024 Q2	$784K	Buy	20,363 +1,236	+6%	+$52K	0.04%	302
2024 Q1	$820K	Buy	19,127 +3,271	+21%	+$135K	0.05%	310
2023 Q4	$588K	Buy	15,856 +9,414	+146%	+$338K	0.04%	363
2023 Q3	$234K	Buy	6,442 +609	+10%	+$21.6K	0.02%	548
2023 Q2	$208K	Sell	5,833 -311	-5%	-$11.2K	0.01%	600
2023 Q1	$219K	Sell	6,144 -279	-4%	-$9.76K	0.02%	538
2022 Q4	$226K	Sell	6,423 -1,170	-15%	-$39K	0.02%	536
2022 Q3	$223K	Buy	7,593 +1,513	+25%	+$57.3K	0.02%	537
2022 Q2	$331K	Hold	6,080	–	–	0.03%	427
2022 Q1	$331K	Buy	+6,080	New	+$330K	0.03%	474
2018 Q4	–	Sell	-3,714	Closed	-$189K	–	699
2018 Q3	$189K	Buy	+3,714	New	+$189K	0.07%	166

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Csenge Advisory Group's GSK Position: Q2 2026 in Review

Csenge Advisory Group increased its GSK (GSK) stake by 16% in Q2 2026, buying an estimated $303K and bringing the position to 41,506 shares worth $2.18M. The position accounts for 0.09% of the portfolio, ranked #196.

Csenge Advisory Group first reported a position in GSK in Q3 2018 and has held it in 19 quarters since. The position peaked at $2.23M in Q4 2025. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Csenge Advisory Group held 41,506 shares of GSK worth $2.18M as of Q2 2026.
Csenge Advisory Group bought 5,720 GSK shares in Q2 2026, an estimated $303K.
GSK made up 0.09% of Csenge Advisory Group's portfolio in Q2 2026, its #196 holding.
Csenge Advisory Group first reported a position in GSK in Q3 2018 and has held it in 19 quarters since.
Csenge Advisory Group's GSK position peaked at $2.23M in Q4 2025.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Csenge Advisory Group's 13F filing for Q2 2026, filed 10 Aug 2026.